Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe update history now includes May 2026 entries (2026-05-08, 2026-05-07, 2026-05), while April 2026 entries (2026-04-22, 2026-04-09, 2026-04) were removed. These entries document when the page was updated, not changes to the study content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedTwo new Chinese study sites were added: Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II in Changsha and Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II in Beijing, bringing total locations to 249 and updating the record to revision v3.5.3.SummaryDifference0.2%

- Check24 days agoChange DetectedThe page footer revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed, indicating a software version update with no changes to the study details.SummaryDifference0.0%

- Check88 days agoChange DetectedThe change is a revision update from v3.4.1 to v3.4.2 with no impact on study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.